Table 8.
Characteristics of L-arginine/NO pathway metabolites as biomarkers for CRC surveillance in inflammatory bowel disease (IBD) patients.
| Marker | Criterion | Sens. and Spec. | Youden (J) Index | LR+ and LR− |
|---|---|---|---|---|
| Arg | ≤212.1 µM | 81.8 and 0% | 0.183 | 0.82 and - |
| ADMA | ≤0.742 µM | 83.9 and 0% | 0.161 | 0.8 and - |
| SDMA | >0.505 µM | 69.3 and 69.2% | 0.386 | 2.3 and 0.44 |
| Cit | ≤70.2 µM | 87.6 and 69.2% | 0.568 | 2.9 and 0.18 |
| DMA | ≤39.3 µM | 35.0 and 100% | 0.350 | - and 0.65 |
| Panel 1 | >0.82 2 | 67.9 and 69.2% | 0.371 | 2.2 and 0.46 |
CRC: Colorectal cancer; Sens.: Sensitivity; Spec.: Specificity; LR: Likelihood ratios; Arg: Arginine; ADMA: Asymmetric dimethylarginine; SDMA: Symmetric dimethylarginine; Cit: Citrulline; DMA: Dimethylamine; 1 a metabolite panel consisting of SDMA and ADMA—metabolites selected in the logistic regression analysis as variables independently from others associated with CRC; 2 predicted probabilities.